Upcoming Pharma Projects in Maharashtra: Key Leads

Projects India currently tracks 137 upcoming pharmaceutical projects in Maharashtra — of which 102 are verified — spanning API manufacturing, bulk drug units, biotech facilities and formulation plants. Three projects were added to our database in the last 90 days alone. Where project costs are recorded, the combined value stands at approximately Rs 9,617 crore, making Maharashtra one of the most active states in India for pharmaceutical capital investment.

Maharashtra pharma pipeline at a glance

Largest upcoming pharma projects in Maharashtra

The table below lists the fifteen largest projects by recorded cost in our Drugs & Pharmaceuticals project database for Maharashtra. Costs are as recorded at the time of tracking and may not reflect subsequent revisions.

Several patterns stand out. Solapur is seeing significant API cluster activity, with both Alivus Life Science and Glenmark Life Sciences each committing Rs 550 crore to separate API units in Mohol — and Glenmark running a concurrent Rs 150 crore formulation line at the same site. Serum Institute of India's combined pipeline in Pune alone exceeds Rs 1,430 crore across vaccines and biotech products. Hemmo Pharmaceuticals is expanding on two Thane sites simultaneously for a combined recorded outlay of Rs 388 crore, part of a broader three-project portfolio totalling about Rs 450 crore.

Where upcoming pharma projects in Maharashtra are concentrated

Geographic spread matters for suppliers planning territory coverage, as the chart below shows.

Solapur leads with 23 projects, driven largely by MIDC-notified pharmaceutical zones in Mohol and surrounding talukas. Thane follows with 18 projects — reflecting the density of established chemical and pharma MIDC estates at Turbhe, Pawane and Tarapur. Pune accounts for 15 projects, anchored by Serum Institute's multi-facility campus and Cipla's Kurkumbh plant. Nagpur (10 projects) and Raigad (9) are emerging corridors, with Nagpur benefiting from its proximity to central India's bulk chemical feedstock supply. Nashik (8 projects) hosts the GSK Pharmaceuticals Rs 500 crore facility at MIDC Ambad, which is already under construction. Palghar (8 projects) has seen both Aarti Pharmalabs and newer entrants filing for approvals or breaking ground at Tarapur MIDC. For field sales teams, Solapur–Pune–Thane forms the primary triangle of active pharma construction, while Nagpur and Nashik represent secondary belts worth covering systematically.

Project stage distribution and what it signals

Understanding where each project sits in its lifecycle tells suppliers and EPC firms how urgent and how certain an opportunity is. The chart below shows the full stage breakdown for all tracked projects in this scope.

The single largest cohort — 58 projects — is Under Approvals, meaning environmental clearances, factory plan sanctions or MIDC allotment processes are in progress. These are early-stage but confirmed-intent projects: the promoter has committed enough to apply. Another 34 projects have Construction Started, making them active buyers of civil works, equipment, instrumentation and utilities right now. Eight projects have Approvals Received and are on the cusp of awarding construction contracts. The 18 projects in Planning are at a stage where promoters are still scoping layout, technology and funding — useful for early relationship-building but not yet procurement-active. Twelve projects are on Hold, which typically reflects financing or regulatory delays; these warrant monitoring rather than active pursuit.

Recently added pharma project leads

Three new pharmaceutical projects were added to our database in the 90 days prior to this report — compared with one in the 90 days before that — pointing to a modest but steady increase in new project activity being logged.

• API & API Intermediates Plant, Palghar (Expansion) — Aarti Pharmalabs Limited, Rs 154 crore, Under Approvals. A capacity expansion at an established Palghar site by one of the more active API producers in western India.
• APIs & Drug Intermediates Project, Nashik (New) — Besi Drugs Private Limited, Rs 5.26 crore, Construction Started. A smaller greenfield unit already breaking ground in Nashik, indicating activity at the MSME end of the market as well.
• API & API Intermediates Project, Tarapur, Palghar (New) — Aadi Rishabh Chemicals LLP, Rs 10 crore, Construction Started. Another Tarapur MIDC entrant at an early construction stage, confirming that the estate continues to attract new API investors alongside larger incumbents.

For suppliers of reactor vessels, HVAC systems, cleanroom fitouts and process instrumentation, the Besi Drugs and Aadi Rishabh projects signal active procurement needs now, even at smaller scale. The Aarti Pharmalabs expansion, at Rs 154 crore, will move to procurement once approvals clear.

Most active promoters across the Maharashtra pharma pipeline

Knowing which promoters are running multiple projects simultaneously helps suppliers prioritise account relationships, as the chart below shows.

Inventys Research Company Private Limited has four tracked projects in Nagpur with a combined cost of about Rs 1,088 crore, making it the highest project-count promoter in our Maharashtra pharma records. Serum Institute of India Limited has the largest recorded investment at approximately Rs 1,430 crore across three projects — all in Pune. GlaxoSmithKline Pharmaceuticals Limited carries a combined recorded cost of approximately Rs 1,000 crore across two projects. Glenmark Life Sciences Limited is running two projects at Solapur totalling Rs 700 crore. Hemmo Pharmaceuticals Private Limited has three projects totalling about Rs 450 crore, all in Thane. For pharma EPC contractors and equipment vendors, these multi-project promoters represent accounts where a single relationship can yield repeated work across a portfolio of sites.

What this means for suppliers and contractors

The 34 projects currently under construction are the most immediately actionable. Civil contractors, structural steel fabricators, cleanroom builders and process equipment suppliers — reactors, distillation columns, centrifuges, granulators, tablet presses, HVAC and purified water systems — are all being procured at this stage. Projects like Serum Institute's Hadapsar vaccines unit (Rs 1,000 crore), Alivus Life Science's Solapur API plant (Rs 550 crore) and Harman Finochem's Amravati bulk drug unit (Rs 464 crore) are live construction sites where procurement decisions are actively being made.

The 58 Under Approvals projects represent the early-engagement window. At this stage, promoters are finalising technology partners, pre-qualifying vendors and sometimes awarding FEED (Front-End Engineering Design) contracts. Suppliers who introduce themselves now — especially to large projects like Ipca Laboratories (Wardha, Rs 553 crore), Glenmark Life Sciences API unit (Solapur, Rs 550 crore) and Inventys Research (Nagpur, Rs 326 crore) — are better positioned to make approved vendor lists before formal tendering begins.

The 8 projects with Approvals Received sit in a brief window between regulatory clearance and construction start — often the period when main EPC contracts and key equipment orders are awarded. The Sahakar Maharshi Shankarrao Kolhe SSK project in Ahmednagar (Rs 159 crore) falls here and warrants close monitoring for imminent tenders. Readers can explore live government tenders on Projects India for public procurement in this sector alongside privately awarded contracts tracked in the project database.

Consulting firms — process design engineers, validation specialists, regulatory affairs consultants, QA/QC firms — are typically engaged early, often before construction approval. The Under Approvals and Planning cohorts are where those relationships begin.

How to track these projects

News releases and industry association lists capture only a fraction of what is actually being built or planned. Projects India's Drugs & Pharmaceuticals project tracker for Maharashtra maintains structured records on 137 upcoming projects in this scope, each with promoter contact details, stage updates, cost data and location specifics updated as projects progress. Subscribers can filter by city, stage, investment size or project type to build a shortlist relevant to their territory and product category. The broader national pharma project database covers the full India pipeline, including comparable clusters in Gujarat and Hyderabad and Telangana. A free sample project report is available for teams evaluating whether the platform fits their BD workflow. For companies looking to identify counterparties — subcontractors, vendors or channel partners — the VendorConnect directory lists verified contractors and suppliers active in the pharmaceutical construction space.